The clinical toxicology of the designer "party pills" benzylpiperazine and trifluoromethylphenylpiperazine

Clinical Toxicology

Volumn 49, Issue 3, 2011, Pages 131-141

  Schep, Leo J ^a   Slaughter, Robin J ^a   Vale, J Allister ^b   Beasley, D Michael G ^a   Gee, Paul ^c  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b CITY HOSPITAL   (United Kingdom)

^c CHRISTCHURCH HOSPITAL   (New Zealand)

Author keywords

Benzylpiperazine; BZP; Dopamine; Drug abuse; Herbal highs; Party pills; Seizures; Serotonin; Stimulant; Sympathomimetic toxidrome; TFMPP; Trifluoromethylphenylpiperazine

Indexed keywords

1 (3 TRIFLUOROMETHYLPHENYL)PIPERAZINE; 1 BENZYLPIPERAZINE DERIVATIVE; AMPHETAMINE; BETA ADRENERGIC RECEPTOR; CATECHOL METHYLTRANSFERASE; CATECHOLAMINE; CENTRAL STIMULANT AGENT; CYTOCHROME P450; DOPAMINE; MONOAMINE; PIPERAZINE; SEROTONIN AGONIST;

AGITATION; ANXIETY; BLOOD BRAIN BARRIER; CATALYSIS; CONFUSION; DEALKYLATION; DIZZINESS; DOPAMINERGIC ACTIVITY; DRUG BLOOD LEVEL; FATALITY; HALF LIFE TIME; HEADACHE; HEART PALPITATION; HUMAN; HYDROXYLATION; INSOMNIA; INTOXICATION; MYDRIASIS; NERVE ENDING; PEER REVIEW; REVIEW; SEIZURE; TOXICOKINETICS; TREMOR; URINE RETENTION; VOMITING;

DESIGNER DRUGS; FEVER; HUMANS; PIPERAZINES; SEIZURES; SEROTONIN RECEPTOR AGONISTS; STREET DRUGS; SUBSTANCE ABUSE DETECTION; SUBSTANCE-RELATED DISORDERS;

EID: 79954476887     PISSN: 15563650     EISSN: 15569519     Source Type: Journal    
DOI: 10.3109/15563650.2011.572076     Document Type: Review

References (102)

1. Johnstone AC, Lea RA, Brennan KA, Schenk S, Kennedy MA, Fitzmaurice PS. Benzylpiperazine: a drug of abuse? J Psychopharmacol 2007; 21:888-894. (Pubitemid 350029185)
2. Glennon RA, McKenney JD, Young R. Discriminative stimulus properties of the serotonin agonist 1-(3-trifluoromethylphenyl) piperazine (TFMPP). Life Sci 1984; 35:1475-1480. (Pubitemid 14027673)
3. Caccia S, Fong MH, Urso R. Ionization constants and partition coefficients of 1-arylpiperazine derivatives. J Pharm Pharmacol 1985; 37:567-570. (Pubitemid 15043042)
4. Joint Formulary Committee. British National Formulary 60. London: Pharmaceutical Press; 2010.
5. Bye C, Munro-Faure AD, Peck AW, Young PA. A comparison of the effects of 1-benzylpiperazine and dexamphetamine on human performance tests. Eur J Clin Pharmacol 1973; 6:163-169.
6. Campbell H, Cline W, Evans M, Lloyd J, Peck AW. Comparison of effects of dexamphetamine and 1-benzylpiperazine in former addicts. Eur J Clin Pharmacol 1973; 6:170-176.
7. Magyar K. Pharmacokinetic aspects of the mode of action of Egyt- 475, a new antidepressant agent. Pol J Pharmacol Pharm 1987; 39:107-112. (Pubitemid 18054030)
8. Magyar K, Fekete MI, Tekes K, Torok TL. The action of trelibet, a new antidepressive agent On [H-3] noradrenaline release from rabbit pulmonary artery. Eur J Pharmacol 1986; 130:219-227. (Pubitemid 17193206)
9. Tekes K, Tothfalusi L, Malomvolgyi B, Herman F, Magyar K. Studies on the biochemical-mode of action of EGYT-475, a new antidepressant. Pol J Pharmacol Pharm 1987; 39:203-211.
10. Malomvolgyi B, Tothfalusi L, Tekes K, Magyar K. Comparison of serotonin agonistic and antagonistic activities of a new antidepressant agent trelibet (Egyt-475) and its metabolite EGYT-2760 on isolated rat fundus. Acta Physiol Hung 1991; 78:201-209.
11. Gee P, Richardson S, Woltersdorf W, Moore G. Toxic effects of BZP-based herbal party pills in humans: a prospective study in Christchurch, New Zealand. N Z Med J 2005; 118:U1784.
12. Gee P, Fountain J. Party on? BZP party pills in New Zealand. N Z Med J 2007; 120:U2422.
13. Lin JC, Bangs N, Lee H, Kydd RR, Russell BR. Determining the subjective and physiological effects of BZP on human females. Psychopharmacology (Berl) 2009; 207:439-446.
14. Drug Enforcement Administration. Schedules of controlled substances; placement of 2,5-dimethoxy-4-(n)-propylthiophenethylamine and N-benzylpiperazine into Schedule I of the Controlled Substances Act. Final rule. Fed Regist 2004; 69:12794-12797.
15. Brennan KA, Lake B, Hely LS, Jones K, Gittings D, Colussi-Mas J, et al. N-benzylpiperazine has characteristics of a drug of abuse. Behav Pharmacol 2007; 18:785-790. (Pubitemid 350076435)
16. Sheridan J, Butler R, Wilkins C, Russell B. Legal piperazinecontaining party pills - a new trend in substance misuse. Drug Alcohol Rev 2007; 26:335-343.
17. Wilkins C, Sweetsur P, Girling M. Patterns of benzylpiperazine/ trifluoromethylphenylpiperazine party pill use and adverse effects in a population sample in New Zealand. Drug Alcohol Rev 2008; 27:633-639.
18. Wilkins C, Sweetsur P. Differences in harm from legal BZP/TFMPP party pills between North Island and South Island users in New Zealand: a case of effective industry self-regulation? Int J Drug Policy 2010; 21:86-90.
19. Sheridan J, Butler R. "They're legal so they're safe, right?" What did the legal status of BZP-party pills mean to young people in New Zealand? Int J Drug Policy 2010; 21:77-81.
20. Fisher D. Human guinea pigs for party pill. New Zealand Herald. Auckland; 27 November 2005.
21. Misuse of Drugs (Classification of BZP) Amendment Act 2008 No 5, Public Act. 2008. http://www.legislation.govt.nz/act/public/ 2008/0005/latest/ DLM1152221.html. 2008. Accessed 23 October 2010.
22. Jones CN, Howard JL, McBennett ST. Stimulus properties of antidepressants in the rat. Psychopharmacology (Berl) 1980; 67:111-118. (Pubitemid 10135173)
23. Cunningham KA, Appel JB. Possible 5-hydroxytryptamine 1 (5HT1) receptor involvement in the stimulus properties of 1-(mtrifluoromethylphenyl) piperazine (TFMPP). J Pharmacol Exp Ther 1986; 237:369-377. (Pubitemid 16092790)
24. Baumann MH, Clark RD, Budzynski AG, Partilla JS, Blough BE, Rothman RB. Effects of "Legal X" piperazine analogs on dopamine and serotonin release in rat brain. Ann N Y Acad Sci 2004; 1025:189-197. (Pubitemid 39643862)
25. Meririnne E, Kajos M, Kankaanpaa A, Seppala T. Rewarding properties of 1-benzylpiperazine, a new drug of abuse, in rats. Basic Clin Pharmacol Toxicol 2006; 98:346-350.
26. Oberlander C, Euvrard C, Dumont C, Boissier JR. Circling behavior induced by dopamine releasers and-or uptake inhibitors during degeneration of the nigrostriatal pathway. Eur J Pharmacol 1979; 60:163-170. (Pubitemid 10185614)
27. Baumann MH, Clark RD, Budzynski AG, Partilla JS, Blough BE, Rothman RB. N-substituted piperazines abused by humans mimic the molecular mechanism of 3,4-methylenedioxymethamphetamine (MDMA, or 'Ecstasy'). Neuropsychopharmacology 2005; 30:550-560. (Pubitemid 40271157)
28. Szucks Z, Szentendrei T, Fekete MI. The effect of EGYT-475 (trelibet) and its metabolites on the potassium-stimulated H-3 noradrenaline release from cortical slices of rat-brain. Pol J Pharmacol Pharm 1987; 39:185-193.
29. Herndon JL, Pierson ME, Glennon RA. Mechanistic investigation of the stimulus properties of 1-(3-trifluoromethylphenyl)piperazine. Pharmacol Biochem Behav 1992; 43:739-748.
30. Fantegrossi WE, Winger G, Woods JH, Woolverton WL, Coop A. Reinforcing and discriminative stimulus effects of 1-benzylpiperazine and trifluoromethylphenylpiperazine in rhesus monkeys. Drug Alcohol Depend 2005; 77:161-168. (Pubitemid 40128194)
31. Pettibone DJ, Williams M. Serotonin-releasing effects of substituted piperazines in vitro. Biochem Pharmacol 1984; 33:1531-1535. (Pubitemid 14105029)
32. Auerbach SB, Rutter JJ, Juliano PJ. Substituted piperazine and indole compounds increase extracellular serotonin in rat diencephalon as determined by in vivo microdialysis. Neuropharmacology 1991; 30:307-310.
33. Auerbach SB, Kamalakannan N, Rutter JJ. TFMPP and RU24969 enhance serotonin release from rat hippocampus. Eur J Pharmacol 1990; 190:51-57. (Pubitemid 20372307)
34. Robertson DW, Bloomquist W, Wong DT, Cohen ML. mCPP but not TFMPP is an antagonist at cardiac 5HT3 receptors. Life Sci 1992; 50:599-605.
35. McKenney JD, Glennon RA. TFMPP may produce its stimulus effects via a 5-HT1B mechanism. Pharmacol Biochem Behav 1986; 24:43-47. (Pubitemid 16180054)
36. Hashimoto K. Effects of benzylpiperazine derivatives on the acute effects of 3,4-methylenedioxymethamphetamine in rat brain. Neurosci Lett 1993; 152:17-20. (Pubitemid 23149302)
37. Antia U, Lee HS, Kydd RR, Tingle MD, Russell BR. Pharmacokinetics of 'party pill' drug N-benzylpiperazine (BZP) in healthy human participants. Forensic Sci Int 2009; 186:63-67.
38. Antia U, Tingle MD, Russell BR. In vivo interactions between BZP and TFMPP (party pill drugs). N Z Med J 2009; 122:29-38.
39. Antia U, Tingle MD, Russell BR. Validation of an LC-MS method for the detection and quantification of BZP and TFMPP and their hydroxylated metabolites in human plasma and its application to the pharmacokinetic study of TFMPP in humans. J Forensic Sci 2010; 55:1311-1318.
40. Staack RF, Fritschi G, Maurer HH. Studies on the metabolism and toxicological detection of the new designer drug N-benzylpiperazine in urine using gas chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2002; 773:35-46. (Pubitemid 34518268)
41. Staack RF, Paul LD, Springer D, Kraemer T, Maurer HH. Cytochrome P450 dependent metabolism of the new designer drug 1-(3-trifluoromethylphenyl) piperazine (TFMPP). In vivo studies in Wistar and Dark Agouti rats as well as in vitro studies in human liver microsomes. Biochem Pharmacol 2004; 39:235-244. (Pubitemid 38112754)
42. Tsutsumi H, Katagi M, Miki A, Shima N, Kamata T, Nakajima K, et al. Metabolism and the urinary excretion profile of the recently scheduled designer drug N-benzylpiperazine (BZP) in the rat. J Anal Toxicol 2006; 30:38-43. (Pubitemid 44270341)
43. Staack RF, Fritschi G, Maurer HH. New designer drug 1-(3- trifluoromethylphenyl) piperazine (TFMPP): gas chromatography/ mass spectrometry and liquid chromatography/mass spectrometry studies on its phase I and II metabolism and on its toxicological detection in rat urine. J Mass Spectrom 2003; 38:971-981. (Pubitemid 37121814)
44. Tsutsumi H, Katagi M, Miki A, Shima N, Kamata T, Nakajima K, et al. Isolation, identification and excretion profile of the principal urinary metabolite of the recently banned designer drug 1-(3- trifluoromethylphenyl) piperazine (TFMPP) in rats. Xenobiotica 2005; 35:107-116. (Pubitemid 40459221)
45. Antia U, Tingle MD, Russell BR. Metabolic interactions with piperazine-based 'party pill' drugs. J Pharm Pharmacol 2009; 61:877-882.
46. Murphy M, Antia U, Chang HY, Han JY, Ibrahim U, Tingle MD, Russell BR. Party pills and drug-drug interactions. N Z Med J 2009; 122:3564.
47. Caccia S, Conti I, Notarnicola A. In-vivo metabolism in the rat and mouse of antrafenine to 1-m-trifluoromethylphenylpiperazine. J Pharm Pharmacol 1985; 37:75-77. (Pubitemid 15189956)
48. Gee P, Richardson S. Researching the toxicity of party pills. Nurs N Z 2005; 11:12-13.
49. Gee P, Gilbert M, Richardson S, Moore G, Paterson S, Graham P. Toxicity from the recreational use of 1-benzylpiperazine. Clin Toxicol (Phila) 2008; 46:802-807.
50. Wikström M, Holmgren P, Ahlner J. A2 (N-benzylpiperazine) a new drug of abuse in Sweden. J Anal Toxicol 2004; 28:67-70. (Pubitemid 38112321)
51. Butler RA, Sheridan JL. Highs and lows: patterns of use, positive and negative effects of benzylpiperazine-containing party pills (BZPparty pills) amongst young people in New Zealand. Harm Reduct J 2007; 4:18.
52. Theron Y, Jansen K, Miles J. Benzylpiperizine-based party pills' impact on the Auckland City Hospital Emergency Department Overdose Database (2002-2004) compared with ecstasy (MDMA or methylene dioxymethamphetamine), gamma hydroxybutyrate (GHB), amphetamines, cocaine, and alcohol. N Z Med J 2007; 120:U2416.
53. Nicholson TC. Prevalence of use, epidemiology and toxicity of 'herbal party pills' among those presenting to the emergency department. Emerg Med Australas 2006; 18:180-184.
54. Lee MO, Vivier PM, Diercks DB. Is the self-report of recent cocaine or methamphetamine use reliable in illicit stimulant drug users who present to the emergency department with chest pain? J Emerg Med 2009; 37:237-240.
55. Kim MT, Hill MN. Validity of self-report of illicit drug use in young hypertensive urban African American males. Addict Behav 2003; 28:795-802. (Pubitemid 36513513)
56. Wilkins C, Girling M, Sweetsur P. The prevalence of use, dependency and harms of legal 'party pills' containing benzylpiperazine (BZP) and trifluorophenylmethylpiperazine (TFMPP) in New Zealand. J Subst Use 2007; 12:213-224. (Pubitemid 46930326)
57. Gee P, Jerram T, Bowie D. Multiorgan failure from 1-benzylpiperazine ingestion - legal high or lethal high? Clin Toxicol (Phila) 2010; 48:230-233.
58. Wood DM, Dargan PI, Button J, Holt DW, Ovaska H, Ramsey J, Jones AL. Collapse, reported seizure - and an unexpected pill. Lancet 2007; 369:1490. (Pubitemid 46635785)
59. Poon WT, Lai CF, Lui MC, Chan AY, Mak TW. Piperazines: a new class of drug of abuse has landed in Hong Kong. Hong Kong Med J 2010; 16:75.
60. Wood DM, Button J, Lidder S, Ramsey J, Holt DW, Dargan PI. Dissociative and sympathomimetic toxicity associated with recreational use of 1-(3-trifluoromethylphenyl) piperazine (TFMPP) and 1- benzylpiperzine (BZP). J Med Toxicol 2008; 4:254-257.
61. Thompson I, Williams G, Caldwell B, Aldington S, Dickson S, Lucas N, et al. Randomised double-blind, placebo-controlled trial of the effects of the 'party pills' BZP/TFMPP alone and in combination with alcohol. J Psychopharmacol 2010; 24:1299-1308.
62. Austin H, Monasterio E. Acute psychosis following ingestion of 'Rapture'. Australas Psychiatry 2004; 12:406-408. (Pubitemid 40103734)
63. Jan RK, Lin JC, Lee H, Sheridan JL, Kydd RR, Kirk IJ, Russell BR. Determining the subjective effects of TFMPP in human males. Psychopharmacology (Berl) 2010; 211:347-353.
64. Alansari M, Hamilton D. Nephrotoxicity of BZP-based herbal party pills: a New Zealand case report. N Z Med J 2006; 119:U1959.
65. Harnett MA. Piperazine-based party drugs: case series of 73 poisonings [conference abstract]. Clin Toxicol (Phila) 2007; 45:373.
66. Klaassen T, Pian KLH, Westenberg HGM, den Boer JA, van Praag HM. Serotonin syndrome after challenge with the 5-HT agonist meta- chlorophenylpiperazine. Psychiatry Res 1998; 79:207-212. (Pubitemid 28346468)
67. Capela JP, Carmo H, Remiao F, Bastos ML, Meisel A, Carvalho F. Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: an overview. Mol Neurobiol 2009; 39:210-271.
68. Schep LJ, Slaughter RJ, Beasley DM. The clinical toxicology of metamfetamine. Clin Toxicol (Phila) 2010; 48:675-694.
69. Balmelli C, Kupferschmidt H, Rentsch K, Schneemann M. Fatal brain oedema after ingestion of ecstasy and benzylpiperazine [German]. Dtsch Med Wochenschr 2001; 126:809-811. (Pubitemid 32661843)
70. Hartung TK, Schofield E, Short AI, Parr MJ, Henry JA. Hyponatraemic states following 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') ingestion. QJM 2002; 95:431-437. (Pubitemid 34814661)
71. Elliott S, Smith C. Investigation of the first deaths in the United Kingdom involving the detection and quantitation of the piperazines BZP and 3-TFMPP. J Anal Toxicol 2008; 32:172-177. (Pubitemid 351362752)
72. Elliott S, Woolacott H, Braithwaite R. The prevalence of drugs and alcohol found in road traffic fatalities: a comparative study of victims. Sci Justice 2009; 49:19-23.
73. Carter B. Coroner probes party pill link in New Year death. The New Zealand Herald. Auckland; 7 January 2007.
74. Wright E, Davies R, Warne C. New killer drug alert as mortgage adviser dies. Sheffield Telegraph. Sheffield; 9 May 2009.
75. Woodford G. Coroner calls for law change after man's 'party drug' death. Nottingham Post. Nottingham; 28 May 2009.
76. Hammer K. After club-goer's death, Health Canada looks at BZP. The Globe and Mail. Toronto; 10 July 2008.
77. McNamara S. 1-benzylpiperazine (BZP) abuse amongst attendees of the Drug Treatment Centre Board. Ir Med J 2009; 102:191.
78. Vorce SP, Holler JM, Levine B, Past MR. Detection of 1- benzylpiperazine and 1-(3-trifluoromethylphenyl)-piperazine in urine analysis specimens using GC-MS and LC-ESI-MS. J Anal Toxicol 2008; 32:444-450.
79. Peters FT, Schaefer S, Staack RF, Kraemer T, Maurer HH. Screening for and validated quantification of amphetamines and of amphetamine- and piperazine-derived designer drugs in human blood plasma by gas chromatography/mass spectrometry. J Mass Spectrom 2003; 38:659-676. (Pubitemid 36818224)
80. Kulig K, Vale JA. Position paper: gastric lavage. J Toxicol Clin Toxicol 2004; 42:933-943.
81. Chyka PA, Seger D, Krenzelok EP, Vale JA. Position paper: singledose activated charcoal. Clin Toxicol (Phila) 2005; 43:61-87.
82. Krenzelok EP, McGuigan M, Lheureux P, Manoguerra AS. Position paper: ipecac syrup. J Toxicol Clin Toxicol 2004; 42:133-143.
83. Downes MA, Healy P, Page CB, Bryant JL, Isbister GK. Structured team approach to the agitated patient in the emergency department. Emerg Med Australas 2009; 21:196-202.
84. Yildiz A, Sachs GS, Turgay A. Pharmacological management of agitation in emergency settings. Emerg Med J 2003; 20:339-346. (Pubitemid 36873910)
85. Whelan KR, Dargan PI, Jones AL, O'Connor N. Atypical antipsychotics not recommended for control of agitation in the emergency department. Emerg Med J 2004; 21:649. (Pubitemid 39232223)
86. Dubin WR, Weiss KJ, Dorn JM. Pharmacotherapy of psychiatric emergencies. J Clin Psychopharmacol 1986; 6:210-222. (Pubitemid 16004569)
87. Henry JA. Amphetamines. In: Ford MD, Delaney KA, Ling LJ, Erickson T, eds. Clinical Toxicology. Philadelphia, PA: Saunders Company; 2001:620-626.
88. McKinney PE, Palmer RB. Amphetamines and derivatives. In: Brent J, Wallace KL, Burkhart KK, Phillips SD, Donovan JW, eds. Critical Care Toxicology: Diagnosis and Management of the Critically Poisoned Patient. Philadelphia, PA: Elsevier Mosby; 2005:761-766.
89. Callaway CW, Clark RF. Hyperthermia in psychostimulant overdose. Ann Emerg Med 1994; 24:68-76. (Pubitemid 24214623)
90. Isbister GK, Calver LA, Page CB, Stokes B, Bryant JL, Downes MA. Randomized controlled trial of intramuscular droperidol versus midazolam for violence and acute behavioral disturbance: the DORM study. Ann Emerg Med 2010; 56:392-401.
91. Shah AS, Eddleston M. Should phenytoin or barbiturates be used as second-line anticonvulsant therapy for toxicological seizures? Clin Toxicol (Phila) 2010; 48:800-805.
92. Guidelines 2000 for cardiopulmonary resuscitation and emergency cardiovascular care. Part 8: advanced challenges in resuscitation: section 2: toxicology in ECC. The American Heart Association in collaboration with the International Liaison Committee on Resuscitation. Circulation 2000; 102:1223-1228.
93. Chiang WK. Amphetamines. In: Flomenbaum NE, Goldfrank LR, Hoffman RS, Howland M, Lewin NA, Nelson LS, eds. Goldfrank's Toxicologic Emergencies.8th ed. New York: McGraw-Hill; 2006:1118-1132.
94. Richards DA, Tuckman J, Prichard BN. Assessment of alphaadrenoceptor and beta-adrenoceptor blocking actions of labetalol. Br J Clin Pharmacol 1976; 3:849-855.
95. Greene SL, Kerr F, Braitberg G. Review article: amphetamines and related drugs of abuse. Emerg Med Australas 2008; 20:391-402.
96. Hall AP, Henry JA. Acute toxic effects of 'Ecstasy' (MDMA) and related compounds: overview of pathophysiology and clinical management. Br J Anaesth 2006; 96:678-685. (Pubitemid 43786681)
97. Rusniak DE, Sprague JE. Hyperthermic syndromes induced by toxins. Clin Lab Med 2006; 26:165-184.
98. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med 2005; 352:1112-1120.
99. Isbister GK, Buckley NA, Whyte IM. Serotonin toxicity: a practical approach to diagnosis and treatment. Med J Aust 2007; 187:361-365.
100. Chan BS, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG. Serotonin syndrome resulting from drug interactions. Med J Aust 1998; 169:523-525. (Pubitemid 28519989)
101. Huerta-Alardin AL, Varon J, Marik PE. Bench-to-bedside review: rhabdomyolysis - an overview for clinicians. Crit Care 2005; 9:158-169. (Pubitemid 40425441)
102. Bosch X, Poch E, Grau JM. Current concepts: rhabdomyolysis and acute kidney injury. N Engl J Med 2009; 361:62-72.